Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an Email Please send an email to stoptrade@acml.in from your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07965081981 Ext: 4 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us, and we appreciate your cooperation in maintaining the integrity of your trading account.
Profit before tax (PBT) stood at Rs 508.98 crore in Q3 FY26, up 4.38% year on year (YoY).
Total expenses increased 7.20% to Rs 1,284.82 crore in Q3 FY26 as against Rs 1,198.44 crore posted in same quarter last year. The cost of materials consumed stood at Rs 147.31 crore (up 26.88% YoY), employee benefit expense was at Rs 196.07 crore (up 45.58% YoY) and finance cost was at Rs 5.48 crore (up 142.47% YoY) during the period under review.
Abbott India is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.
Shares of Abbott India fell 1.06% to currently trade at Rs 26,609.95 on the BSE.
Powered by Capital Market - Live News